In vivo evaluation in cynomolgus monkey brain and metabolism of [ 18F]fluorodeprenyl: A new MAO-B pet radioligand

Synapse

Volumn 66, Issue 4, 2012, Pages 323-330

  Nag, Sangram ^a   Varrone, Andrea ^a   Tóth, Miklós ^a   Thiele, Andrea ^b   Kettschau, Georg ^b   Heinrich, Tobias ^b   Lehmann, Lutz ^b   Halldin, Christer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b BAYER PHARMA AG   (Germany)

Author keywords

Astrocytes; Fluorine 18; Kinetics; Metabolites; Monoamine oxidase; Non human primate; PET

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; FLUORODEPRENYL F 18; RADIOLIGAND; SELEGILINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG METABOLISM; DRUG RETENTION; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; HAPLORHINI; IN VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; THALAMUS;

ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORINE RADIOISOTOPES; MACACA FASCICULARIS; MONOAMINE OXIDASE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SELEGILINE;

EID: 84856396473     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.21514     Document Type: Article

References (30)

1. Andersson J, Truong P, Halldin C. 2009. In-target produced [11C]methane: Increased specific radioactivity. Appl Radiat Isot 67: 106-110.
2. Andrews JM, Nemeroff CB. 1994. Contemporary management of depression. Am J Med 97: S24-S32.
3. Arnett CD, Fowler JS, MacGregor RR, Schlyer DJ, Wolf AP, Langstrom B, Halldin C. 1987. Turnover of brain monoamine oxidase measured in vivo by positron emission tomography using L-[11C]deprenyl. J Neurochem 49: 522-527.
4. Bach AWJ, Lan NC, Bruke DJ, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC. 1988. Molecular-cloning of human monoamine oxidase-A and oxidase-B (MAO-A and MAO-B). FASEB J 2: A1733-A1733.
5. Blaschko H, Richter D, Schlossmann H. 1937. The inactivation of adrenaline. J Physiol 90: 1-17.
6. Cesura AM, Pletscher A. 1992. The new generation of monoamine oxidase inhibitors. Prog Drug Res 38: 171-297.
7. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. 1997. Special report: The 1996 guide for the care and use of laboratory animals. ILAR J 38: 41-48.
8. Cumming P, Yokoi F, Chen A, Deep P, Dagher A, Reutens D, Kapczinski F, Wong DF, Gjedde A. 1999. Pharmacokinetics of radiotracers in human plasma during positron emission tomography. Synapse 34: 124-134.
9. Drukarch B, van Muiswinkel FL. 2000. Drug treatment of Parkinson's disease-Time for phase II. Biochem Pharmacol 59: 1023-1031.
10. Fowler JS, Macgregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, Christman D, Logan J, Smith M, Sachs H, Aquilonius SM, Bjurling P, Halldin C, Hartvig P, Leenders KL, Lundqvist H, Oreland L, Stalnacke CG, Langstrom B. 1987. Mapping human-brain monoamine oxidase-A and oxidase-B with C-11 labeled suicide inactivators and PET. Science 235: 481-485.
11. Fowler JS, Wang GJ, Logan J, Xie S, Volkow ND, MacGregor RR, Schlyer DJ, Pappas N, Alexoff DL, Patlak C, Wolf AP. 1995. Selective reduction of radiotracer trapping by deuterium substitution: Comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med 36: 1255-1262.
12. Halldin C, Swahn C-G, Farde L, Sedvall G. 1995. PET for Drug Development and Evaluation. Radioligand disposition and metabolism. In: Comar D, editor. Kluwer Academic Publishers, Dordrecht, Netherlands. p 55-65.
13. Hare ML. 1928. Tyramine oxidase: A new enzyme system in liver. Biochem J 22: 968-979.
14. Holtzheimer PE, Nemeroff CB. 2006. Emerging treatments for depression. Expert Opin Pharmacother 7: 2323-2339.
15. Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrumsager B. 1993. PET examination [C-11] NNC-687 and [C-11] NNC-756 as new radioligans for the D-1-dopamine receptor. Psychopharmacology 113: 149-156.
16. Kim HJ, Zeeberg BR, Reba RC. 1990. Theoretical investigation of the estimation of relative regional neuroreceptor concentration from a single SPECT or PET image. IEEE Trans Med Imaging 9: 247-261.
17. Lajtha A, Sershen H, Cooper T, Hashim A, Gaal J. 1996. Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration. Neurochem Res 21: 1155-1160.
18. Levitt P, Pintar JE, Breakefield XO. 1982. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79: 6385-6389.
19. MacGregor RR, Fowler JS, Wolf AP, Halldin C, Langstrom B. 1988. Synthesis of suicide inhibitors of monoamine oxidase: Carbon-11 labeled clorgyline, L-deprenyl and D-deprenyl. J Labelled Compd Radiopharm 25: 1-9.
20. Magyar K. 2011. The pharmacology of selegiline. Int Rev Neurobiol 100: 65-84.
21. Nag S, Lehmann L, Heinrich T, Thiele A, Kettschau G, Nakao R, Gulyas B, Halldin C. 2011. Synthesis of three novel fluorine-18 labelled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B). J Med Chem 54: 7023-7029.
22. Nakamura S, Kawamata T, Akiguchi I, Kameyama M, Nakamura N, Kimura H. 1990. Expression of monoamine oxidase B activity in astrocytes of senile plaques. Acta Neuropathol 80: 419-425.
23. Plenevaux A, Fowler JS, Dewey SL, Wolf AP, Guillaume M. 1991. The synthesis of no-carrier-added DL-4-[18F]fluorodeprenyl via the nucleophilic aromatic substitution reaction. Int J Rad Appl Instrum A 42: 121-127.
24. Sandell J, Langer O, Larsen P, Dolle F, Vaufrey F, Demphel S, Crouzel C, Halldin C. 2000. Improved specific radioactivity of the PET radioligand [C-11]FLB 457 by use of the GE Medical Systems PETtrace MeI MicroLab. J Labelled Compd Radiopharm 43: 331-338.
25. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, Richards JG. 1994. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62: 15-30.
26. Shin HS. 1997. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 25: 657-662.
27. Singer TP, Ramsay RR. 1995. Flauoprotein structure and mechanism 2. Monoamine oxidases: Old friends hold many surprises. FASEB J 9: 605-610.
28. Tipton KF, Boyce S, O'Sullivan J, Davey GP, Healy J. 2004. Monoamine oxidases: Certainties and uncertainties. Curr Med Chem 11: 1965-1982.
29. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L. 2009. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging 36: 1639-1650.
30. Zeller EA. 1938. Über den enzymatischen Abbau von Histamin und Diaminen. 2. Mitteilung. Helv Chim Acta 21: 880-890.